Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 (MALAT1) interacts with estrogen receptor and predicted poor survival in breast cancer

Oncotarget

Volumn 7, Issue 25, 2016, Pages 37957-37965

  Huang, Nai Si ^a,b   Chi, Ya Yun ^a,b   Xue, Jing Yan ^a,b   Liu, Meng Ying ^a,b   Huang, Sheng ^a,b   Mo, Miao ^a,b   Zhou, Shu Ling ^a,b   Wu, Jiong ^a,b,c  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c State Key Laboratory Oncology in South China   (China)

Author keywords

Breast cancer; Estrogen receptor; Long non coding RNA; MALAT1

Indexed keywords

CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; LONG UNTRANSLATED RNA; METASTASIS ASSOCIATED IN LUNG ADENOCARCINOMA TRANSCRIPT 1; PROGESTERONE RECEPTOR; TAMOXIFEN; UNCLASSIFIED DRUG; MALAT1 LONG NON-CODING RNA, HUMAN; TUMOR MARKER;

ADULT; AGE; ARTICLE; BREAST CANCER CELL LINE; CANCER PROGNOSIS; CANCER STAGING; CCND1 GENE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA BASE; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MCF10A CELL LINE; MENOPAUSE; PGR GENE; PROPORTIONAL HAZARDS MODEL; PROTEIN PROTEIN INTERACTION; RECURRENCE FREE SURVIVAL; TUMOR VOLUME; UPREGULATION; ADENOCARCINOMA; BIOSYNTHESIS; GENETICS; LUNG TUMOR; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR CELL LINE;

ADENOCARCINOMA; BIOMARKERS, TUMOR; CELL LINE, TUMOR; FEMALE; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; RECEPTORS, ESTROGEN; RNA, LONG NONCODING; SURVIVAL ANALYSIS;

EID: 84978131621     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.9364     Document Type: Article

References (31)

1. Mattick JS. The genetic signatures of noncoding RNAs. PLOS Genet. 2009; 5:e1000459. doi: 10.1371/journal. pgen.1000459.
2. Huarte M, Rinn JL. Large non-coding RNAs: missing links in cancer? Hum Mol Genet. 2010; 19:R152-161. doi: 10.1093/hmg/ddq353.
3. Tsai MC, Spitale RC, Chang HY. Long intergenic noncoding RNAs: new links in cancer progression. Cancer Res. 2011; 71:3-7. doi: 10.1158/0008-5472.
4. Ji P, Diederichs S, Wang W, Böing S, Metzger R, Schneider PM, Tidow N, Brandt B, Buerger H, Bulk E, Thomas M, Berdel WE, Serve H, et al. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene. 2003; 22:8031-41.
5. Shen L, Chen L, Wang Y, Jiang X, Xia H, Zhuang Z. Long noncoding RNA MALAT1 promotes brain metastasis by inducing epithelial-mesenchymal transition in lung cancer. J Neuro-Oncol. 2015; 121:101-8. doi: 10.1007/s11060-014-1613-0.
6. Schmidt LH, Spieker T, Koschmieder S, Humberg J, Jungen D, Bulk E, Hascher A, Wittmer D, Marra A, Hillejan L, Wiebe K, Berdel WE, Wiewrodt R, et al. The long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth. J Thorac Oncol. 2011; 6:1984-92. doi: 10.1097/JTO.0b013e3182307eac.
7. Jiao F, Hu H, Yuan C, Wang L, Jiang W, Jin Z, Guo Z, Wang L. Elevated expression level of long noncoding RNA MALAT-1 facilitates cell growth, migration and invasion in pancreatic cancer. Oncol Rep. 2014; 32:2485-92. doi: 10.3892/or.2014.3518.
8. Okugawa Y, Toiyama Y, Hur K, Toden S, Saigusa S, Tanaka K, Inoue Y, Mohri Y, Kusunoki M, Boland CR, Goel A. Metastasis-associated long non-coding RNA drives gastric cancer development and promotes peritoneal metastasis. Carcinogenesis. 2014; 35:2731-9. doi: 10.1093/carcin/bgu200.
9. Han Y, Liu Y, Nie L, Gui Y, Cai Z. Inducing cell proliferation inhibition, apoptosis, and motility reduction by silencing long noncoding ribonucleic acid metastasis-associated lung adenocarcinoma transcript 1 in urothelial carcinoma of the bladder. Urology. 2013; 81:209.e1-7. doi: 10.1016/j. urology.2012.08.044.
10. Gutschner T, Hämmerle M, Diederichs S. MALAT1-a paradigm for long noncoding RNA function in cancer. J Mol Med. 2013; 91:791-801. doi: 10.1007/s00109-013-1028-y.
11. Guffanti A, Iacono M, Pelucchi P, Kim N, Soldà G, Croft LJ, Taft RJ, Rizzi E, Askarian-Amiri M, Bonnal RJ, Callari M, Mignone F, Pesole G, et al. A transcriptional sketch of a primary human breast cancer by 454 deep sequencing. BMC Genomics. 2009; 10:163. doi: 10.1186/1471-2164-10-163.
12. Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, Van Tine BA, Hoog J, Goiffon RJ, Goldstein TC, Ng S, Lin L, Crowder R, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012; 486:353-60. doi: 10.1038/nature11143.
13. Tripathi V, Ellis JD, Shen Z, Song DY, Pan Q, Watt AT, Freier SM, Bennett CF, Sharma A, Bubulya PA, Blencowe BJ, Prasanth SG, Prasanth KV. The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. Mol Cell. 2010; 39: 925-38. doi: 10.1016/j.molcel.2010.08.011.
14. Ga H, Chakraborty G, Lee-Lim AP, Mavrakis KJ, Wendel HG, Giancotti FG. Forward genetic screens in mice uncover mediators and suppressors of metastatic reactivation. Proc Natl Acad Sci U S A. 2014; 111:16532-7. doi: 10.1073/pnas.1403234111.
15. Arun G, Diermeier S, Akerman M, Chang KC, Wilkinson JE, Hearn S, Kim Y, MacLeod AR, Krainer AR, Norton L, Brogi E, Egeblad M, Spector DL. Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA loss. Genes Dev. 2016; 30:34-51. doi: 10.1101/gad.270959.115.
16. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C, Schultz N. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013; 6:1. doi: 10.1126/scisignal.2004088.
17. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012; 2:401-4. doi: 10.1158/2159-8290.CD-12-0095.
18. Gyorffy, B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, Szallasi Z. An online survival analysis tool to rapidly assess the effect of 22, 277 genes on breast cancer prognosis using microarray data of 1, 809 patients. Breast Cancer Res Treat. 2010; 123:725-31. doi: 10.1007/s10549-009-0674-9.
19. Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. Mol Cell. 2011; 43:904-14. doi: 10.1016/j. molcel.2011.08.018.
20. Guttman M, Rinn JL. Modular regulatory principles of large non-coding RNAs. Nature. 2012; 482:339-46. doi: 10.1038/nature10887.
21. Zong X, Tripathi V, Prasanth KV. RNA splicing control: yet another gene regulatory role for long nuclear noncoding RNAs. RNA Biol. 2011; 8:968-77. doi: 10.4161/rna.8.6.17606.
22. Hutchinson JN, Ensminger AW, Clemson CM, Lynch CR, Lawrence JB, Chess A. A screen for nuclear transcripts identifies two linked noncoding RNAs associated with SC35 splicing domains. BMC Genomics. 2007; 8:39.
23. Praz V, Jagannathan V, Bucher P. CleanEx: a database of heterogeneous gene expression data based on a consistent gene nomenclature. Nucleic Acids Res. 2004; 32:D542-7.
24. Xu C, Yang M, Tian J, Wang X, Li Z. MALAT-1: a long non-coding RNA and its important 3' end functional motif in colorectal cancer metastasis. Int J Oncol. 2011; 39:169-75. doi: 10.3892/ijo.2011.1007.
25. Fellenberg J, Bernd L, Delling G, Witte D, Zahlten-Hinguranage A. Prognostic significance of drug regulated genes in high grade osteosarcoma. Mod Pathol. 2007; 20:1085-94.
26. Jin C, Yan B, Lu Q, Lin Y, Ma L. Reciprocal regulation of Hsa-miR-1 and long noncoding RNA MALAT1 promotes triple-negative breast cancer development. Tumour Biol. 2015 Epub ahead of print.
27. Chou J, Wang B, Zheng T, Li X, Zheng L, Hu J, Zhang Y, Xing Y, Xi T. MALAT1 induced migration and invasion of human breast cancer cells by competitively binding miR-1 with cdc42. Biochem Biophys Res Commun. 2016. Epub ahead of print. doi: 10.1016/j.bbrc.2016.02.102.
28. Feng T, Shao F, Wu Q, Zhang X, Xu D, Qian K, Xie Y, Wang S, Xu N, Wang Y, Qi C. miR-124 downregulation leads to breast cancer progression via LncRNA-MALAT1 regulation and CDK4/E2F1 signal activation. Oncotarget. 2016 Epub ahead of print. doi: 10.18632/oncotarget.7578.
29. Bamodu OA, Huang WC, Lee WH, Wu A, Wang LS, Hsiao M, Yeh CT, Chao TY. Aberrant KDM5B expression promotes aggressive breast cancer through MALAT1 overexpression and downregulation of hsa-miR-448. BMC cancer. 2016; 16:160. doi: 10.1186/s12885-016-2108-5.
30. Loi S, Haibe-Kains B, Desmedt C, Wirapati P, Lallemand F, Tutt AM, Gillet C, Ellis P, Ryder K, Reid JF, Daidone MG, Pierotti MA, Berns EM, et al. Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics. 2008; 9:239. doi: 10.1186/1471-2164-9-239.
31. Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, Gillet C, Ellis P, Harris A, Bergh J, Foekens JA, Klijn JG, Larsimont D, Buyse M, et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol. 2007; 25:1239-46.